Last reviewed · How we verify
NCT07161570: VR-SAD
Virtual Reality Digital Therapeutics for Seasonal Affective Disorder
NA trial testing Virtual Reality (VR) Intervention in Seasonal Affective Disorder (SAD) in 60 participants. Not yet recruiting.
31 March 2026
Quick facts
| Lead sponsor | Anglia Ruskin University |
|---|---|
| Phase | NA |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | treatment |
| Enrollment | 60 |
| Start date | 27 October 2025 |
| Primary completion | 31 March 2026 |
| Estimated completion | 31 December 2026 |
Drugs / interventions tested
- Virtual Reality (VR) Intervention
- Light Box (LB) intervention
Conditions studied
- Seasonal Affective Disorder (SAD) — all drugs for Seasonal Affective Disorder (SAD) →
Sponsor
Anglia Ruskin University
Who can join
18 and older, any sex, with Seasonal Affective Disorder (SAD). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Seasonal Affective Disorder (SAD) is commonly treated with bright light therapy. Virtual reality (VR) is an immersive computer-generated environment, which has been used to treat mental health difficulties, such as depression, social anxiety and stress. This study aims to compare the use of VR with bright light therapy in treating SAD. Participants will be randomly allocated to either the VR condition or the light box condition and instructed to use the respective device every day for 14 days.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07161570
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Virtual Reality (VR) Intervention
Trials testing the same drug.
- NCT07221409 — Virtual Reality Intervention to Improve Psychological Symptom Burden for Cancer Patients Undergoing Treatment · NA · recruiting
Other Anglia Ruskin University trials
Trials by the same sponsor.
- NCT07008586 — The Impact of OliPhenolia® Supplementation on Exercise Induced Inflammation and Functional Movement in Humans. · NA · completed
- NCT07210099 — The Effect of Short-term Supplementation of OliPhenolia® on Fat Oxidation · NA · recruiting
- NCT06844396 — The Impact of NICU Music Therapy for Preterm Infants and Caregivers · NA · completed
- NCT07497113 — The Effects of Commercially Available High Protein Drink on Amino Acid Bioavailability and Recovery From Muscle Fatiguin · NA · completed
- NCT06512272 — Video-recOrded hospItal dischaRge (VOIR) · NA · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07161570 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Anglia Ruskin University
- Last refreshed: 8 September 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07161570.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing